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IMMUNOLOGICAL CAPABILITIES OF PATIENTS WITH
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AND W. KENNETH BLAYLOCK, M.D.
Although atopic dermatitis occurs in patients
having family histories of asthma and allergic
rhinitis, it is not established that these patients
react differently immunologically from normal
people or from patients with other forms of
eczema. The only known immunological differ-
ence between normal people and patients with
atopic dermatitis is the greater ease with which
the atopic individual forms reaginic antibodies
to environmental antigens. Fireman et ol (1)
have recently reported the presence of reagin in
the immunoglobulin A fraction of the serum. It
has also been reported in other immunoglobu-
lins (2).
The purposes of this study were to determine
the ability of patients with atopic dermatitis
to make circulating antibodies to parcnterally
administered primary antigens, to establish the
immunoglobulin sequences following the injec-
tion of the antigens and to determine delayed
immune responses.
MATERIALS AND METHODS
Selection of Patients
Patients were classified as having atopic derma-
titis on the basis of morphology and distribution
of skin lesions and a positive family history of
asthma, allergic rhinitis or atopic dermatitis. Pas-
sive transfer tests were performed using the
serum from sixteen of these patients. Control
subiects included patients with chronic eczematoid
dermatitis of unknown etiology, patients with acne,
patients with psoriasis and patients without any
evidence of skin disease. None of the control
subjects were in negative nitrogen balance. Twelve
patients with asthma or hay fever without a
dermatitis were also studied.
Primary Immune Responses
c) VI entigen.' Thirty patients with atopic
dermatitis, twelve patients with asthma and/or
* From the Department of Dermatology and
Syphilology, Medical College of Virginia, Rich-
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'The VI antigen is a polysaccharide obtained
from E. coli 53/968. This antigen was furnished
by Dr. Marion Webster of the National Heart
Institute, Bethesda, Maryland.
allergic rhinitis, fifteen patients with psoriasis,
eleven patients with chronic hand eczema,, ten
patients with nummular eczema, nine patients
without a skin disorder and three patients with
acne vulgaris were injected subcutaneously with
100 pg of VI antigen. Serum was obtained prior
to the injection and at one, three, and six weeks
post injection. Hemagglutination titers were de-
termined by the technic of Landy (3).
b) Brucellin. Twenty patients with atopic der-
matitis, three patients with psoriasis, two patients
with nummular eczema, three patients with chronic
hand eczema, and three patients without skin
disease were injected subcutaneously with 0.5 cc
of Brucellin.2 Serum was obtained prior to the in-
icction of the antigen and at one and three weeks
after injection. Agglutination titers were deter-
mined by a standard serum agglutination technic
(4,5).
Immuno globulin Sequence
Immunoglobulin G and immunoglobulin M
were separated from the serum obtained before in-jection and at one, three, and six weeks after
injection of the VI antigen. Separation of these
immunoglobulins was obtained by using the
DEAE cellulose column fractionation according
to a modified technic of Fahey (6) as follows.
The serum globulins were separated from the
serum by a "salting out" technic using ammonium
sulfate. In this "salting out" procedure, the serum
(2.5—3.5 cc) was first diluted with an equal volume
of distilled water followed by the addition of a
1:1 volume of 3.6M ammonium sulfate titrated
to a pH 7.4 with concentrated ammonium hy-
droxide. After settling for four hours at 4°C the
mixture was centrifuged at 2500 rpm for thirty min-
utes. The supcrnatc was discarded. The precipitate
was redissolvcd with as much distilled water as
needed and dialyzed for four hours against the
initial buffer used on the columns.
DEAE anion exchange columns were prepared
using two grams of diethylaminocthyl (DEAE)
cellulose packed in equilibrium with the initial
buffer, a 0.02M solution in respect to phosphate.
The phosphate buffer was prepared from monobasic
and dibasic sodium phosphate titrated to a pH
of 8. Following the addition of the dialyzed serum
to the column, 40 to 50 ml of 0.02M phosphate
buffer were allowed to run through the column by
means of gravity flow. The fractions were col-
2 The Brucellin antigen was obtained from
Merck and Co. It is a clear, cell-free culture fil-
trate prepared from selected virulent strains of
Brucella abortus, Bruce Ila melitensis and Brucella
sins suspended in physiologic saline with 0.5%
phenol added as a preservative.
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lected in 5 ml samples, and their optical densities
measured at 280 mu on the Beckman B spectrom-
eter. These fractions contain primarily immuno-
globulin G or 78. Once the 78 globulins had been
collected an elution gradient was begun using
20 ml each of 0.02M and 02M phosphate buffer.
These fractions, containing 198 globulin, were
measured in the same manner as the 78. All
procedures were done in a cold room at 4°C.
Titers of antibodies to the VI antigen were deter-
mined by the technic of Landy (3) on the immuno-
globulin G and M fractions obtained from the
serums in patients immunized as described above.
Delayed Immune Responses
a) Skin Tests. Thirty-two patients with atopic
dermatitis, seven patients with chronic hand
eczema, four patients with psoriasis and three
patients with nummular eczema bad intradermal
injections of 0.1 cc of each of the following bac-
terial, viral and mycelial antigens:
1) Purified protein derivative (P.P.D.) first
strength (0.00002 mg/ml);
2) P.P.D. second strength (0.005 mg/ml);
3) Coccidiodin in a 1:100 solution (Cutter
Labs.);
4) Lymphogranuloma venereum antigen (Ly-
granum, Lederle Labs.);
5) Lymphogranuloma venercum control (Chick
embryo origin, Lederle Labs.);
6) Histoplasmin test solution equivalent in
activity to N.I.H. Reference Histoplasmin diluted
for use (Parke, Davis, and Co.);
7) Schick test (Wyeth Labs.);
8) Schick test control (Wyeth Labs.);
9) Oidiomycin (Hollister-Stier Labs.);
10) Trichophyton (Hollister-Stier Labs.);
11) Mumps skin test antigen 1 cc containing
20 complement-fixing units (Eli Lilly & Co.);
12) Dick (Wyeth Labs.).
A test was considered positive when there were
at least 5 mm of induration and erythema. Test
sites were observed at thirty minutes, twenty-
four and forty-eight hours and five days.
b) 2,4 Dinitrochlorobenzene. Thirty-nine pa-
tients with atopic dermatitis, fifteen patients with
psoriasis, ten patients with nummular eczema,
thirteen patients with chronic hand eczema, and
two patients with acne vulgaris were sensitized
to dinitrochlorobenzene according to the technic
of Epstein and Kligman (7). In this sensitization
technic, 0.1 cc of a 2% solution of DNCB in
acetone was applied to an apparently area of un-
involved skin 2.2 cm in diameter on the volar
aspect of the right forearm. Once the solvent
had evaporated, a protective dressing was applied
and left in place for eight days. When possible
the flare reaction (8) at seven to ten days was ob-
served. The sensitization was evaluated at three
to four weeks using a 0.1 cc of a 0.1% solution of
DNCB applied in the same manner on the oppo-
site forearm. The tests were read at two days,
four days, and one week after the test dose was
applied. Induration and/or vesiculation were the
criteria used for a positive reaction.
c) Homografts. Skin homografts were done in
four patients with atopic dermatitis, two patients
with nummular eczema and three patients with
sarcoidosis. Each patient received two homo-
grafts. The area of skin used for grafting was the
back of the patients in both donors and recipient.
This skin was prepared by scrubbing with pilisohex
followed by the application of Benzalkonium
chloride. One or two percent Xylocaine was used
locally for anesthesia. Full thickness grafts were
obtained with an 8 mm manual punch. Grafts
were placed on the back of the recipient and held
in place by four 5—0 silk sutures. Sterile dressings
were applied. Grafts were inspected daily for the
first week and every other day for the second and
third weeks. Sutures were removed after four days.
Biopsy specimens, 2 mm diameter, were obtained
from the borders at appropriate intervals.
Auto grafts
Autografts (Fig. 1) were done using a similar
technic as described for the homografts. Fourteen
patients with atopic dermatitis were grafted with
a total of ninety-four grafts. The sets of auto-
grafts done in these patients were as follows: nor-
mal skin to normal skin; normal skin to diseased
skin, diseased skin to normal skin, diseased skin
to diseased skin.
RESULTS
Primary Immune Response
The published reports arc not clear as to
whether a patient with atopic dermatitis is
more allergic than a normal person or another
person having chronic eczcmntous dermatitis un-
related to atopy.
a) VI antigen. The VI antigen, considered a
primary antigen, elicits a 7S antibody response
in most subjects. The median titer in thirty
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TABLE I
Results of production of circulating
antibodies to VI antigen
Patient
8—10 days
post-immunization
18—21 days
pest-immunization
48—50 days
post-immunization
PATIENTS WITH ATOPIC DERMATITIS
PRODUCTION OF CIRCULATING ANTIBODIES
TO BRUCELLIN
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TABLE II
Results of production of circulating
antibodies to bruceltin
1:32
1:128
1:64
1:8
1:128
1:64
1:256
1:256
1:64
1:32
1:64
1:128
1:128
1: 1024
1:64
1:32
1:256
1:128
1:4
1:64
1:512
1:256
1:8
1:4
1:512
1:128
1:4
1:4
1:64
1:256
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
1:8
1:2
1:8
1:64
1:128
1:64
1:64
1:2
1:128
1:8
1:4
1:32
1:32
1:128
1:64
1:32
1:2
1:128
1:2
1:64
1:4
1:16
1:128
1:2
1:2
1:32
1:2
1:2
1:64
1:2
1:64
1:128
1:2
1:4
1:256
1:256
1:32
1:512
1:4
1:256
1:32
1:4
1:32
1:128
1:64
1:64
1:128
1:64
1:256
1:128
1:64
1:32
1:32
1:256
1:128
1:32
1:64
1:64
1:128
1:128
1:2
1:64
1:64
1:256
1:32
1:16
1:128
1:64
1:8
1:8
1:64
1:512
1:128
1:512
1:32
1:1024
1:256
1:256
1:128
1:1024
1:16
1:512
1:32
1:64
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
First Week
1:160
1:40
1:80
1:160
1:160
1:80
1:20
1:80
1:160
1:40
1:160
1:40
1:40
1:80
1:20
1:160
1:160
1:320
1:40
1:40
Third Week
1:320
1:80
1:80
1:640
1:160
1:160
1:20
1:80
1:160
1:40
1:160
1:40
1:80
1:160
1:20
1:160
1:80
1:320
1:160
1:40
Note: Patients *31 to 42 have asthma or allergic
rhinitis.
patients With atopie dermatitis one week after
injection was 1:16 (1:2—1:512), and both
three and six weeks after injection it was 1: 64
(1:2—1 : 1024). Titers in patients with chronic
eezematous dermatitis, psoriasis, nummular
eczema and normal controls were similar to
other eezematous patients in their responses to
the VI antigen.
Brueellin, also a primary antigen in most
subjects, elicits a 19S immunoglobulin response
for the first four months (9). In twenty-one
patients with atopie dermatitis, the average ag-
glutination titer one week after injection was
1: 80 and three weeks after injection was
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1: 160. These responses were similar to those
of normal controls as well as those of patients
with nummular eczema, chronic eezematous
dermatitis, and psoriasis. Patients with atopie
dermatitis responded in a normal manner to the
Brueellin antigen and this is similar to the sero-
logical responses of patients with other forms
of eczema.
Immune Globulin Sequence
At least two distinct classes of antibodies are
known to be formed in a characteristic sequence
following the injection of an antigen. The first
immunoglobulin response is the rise of gamma
M or 1gM. This response usually ends in about
2—3 weeks and gamma G or IgG is then the
specific immunoglobulin produced. The normal
patient first produces his antibody to an antigen
in the 1gM fraction at the end of one week. At
the end of three weeks the immunoglobulin is
present in both the gamma M and G fractions
and at the end of 6 weeks the immunoglobulin
is present in gamma G fraction only. Patients
with atopie dermatitis responded in that man-
ner in the immunoglobulin sequence (Table III).
Antibody titers in the immunoglobulin A frac-
tion of the serum were not assessed. These data
suggest that the atopie individual is similar to
normal patients and other patients with chronic
eczema in his immunoglobulin sequence follow-
ing the injection of the VI antigen.
Delayed Immune Response
a) Skin Tests. Thirty-one of thirty-two pa-
tients with atopie dermatitis receiving the van-
ous antigens intradermally had a positive reac-
tion to one or several antigens (Table IV).
All patients with psoriasis, nummular eczema,
and chronic hand eczema that received the skin
tests, developed a positive reaction to at least
one of the intradermal antigens.
b) DNCB. A skin sensitization with DNCB
was provoked in thirty of thirty-nine (76.9%)
patients with atopie dermatitis, six of six pa-
tients with asthma and/or allergic rhinitis,
thirteen of fifteen patients (87%) with psoria-
sis, nine of ten (90%) patients with nummular
eczema, twelve of thirteen (92.3%) patients
with chronic hand eczema but without atopie
background, and in the two patients with acne
vulgaris (Table V). DNCB will sensitize over
90% of the normal population as shown in other
studies (7).
c) Homografts. Four patients with atopie
dermatitis received eight homografts, two pa-
tients with nummular eczema received four
homografts and three patients with sarcoidosis
received six homografts (Table VI). All the pa-
tients rejected the homografts within 14—19
days. Second set rejections were not deter-
mined.
Auto grafts
Fourteen patients with atopie dermatitis re-
ceived autografts in the manner described
above. The results are recorded in Table VII.
When the normal skin was grafted to a normal
site, 90% of the grafts took. When the normal
skin in an atopie patient was autografted to a
TABLE III
Immunoglobulin sequence
Serum
Titer
Prior
Iuj.
Prior Inj.
7S 19S
Serum
Titer
Our
week
Ooe week I
J
I
7S
1
Serum
Titer
Three
weeks
Three weeks
'
iS 19S
Serum
I Titer
I Six weeks
Six weeks
'
7S t9S
Controls
1
2
3
0
0
0
0
0
0
0
0
0
1:64
1:4
1:64
1:16
0
1:16
1:4
1:2
0
1:64
1:64
1:128
1:32 1:4
1:2 lo
1:4 0
Atopie Dermatitis
1
2
3
0
0
0
0
0
0
0
0
0
1:32
1:16
1:4
0
0
0
1:4
1:4
1:4
1:64
1:256
1:32
0 1:2
1:128 j 1:32
1:2
11:4
1:128
1:512
1:64
1:211:8
1:8 I 0
1:410
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TABLE IV
Response to bacterial and mycelial antigens
diseased site 53% of the grafts took. Only 29%
of the grafts from diseased skin to normal skin
were successfully autografted to normal skin.
DISCUSSION
Primary Immune Response
Patients with atopic dermatitis responded in
a normal manner to a parenterally adminis-
tered primary antigen (VI polysaccharide).
This normal response does not mean that pa-
tients with atopic dermatitis have the same in-
cidence of sensitization to primary antigens as
that of a normal population since almost all
normal patients injected with the antigen pro-
duce an antibody titer. To determine whether
the atopic individual is more easily sensitized,
an antigen which does not produce an antibody
titer in a high percentage of normal people
should be administered to determine if a
greater percentage of the atopic individuals be-
come sensitized to that antigen. The antibody
response to Brucellin was normal also. These
observations would suggest that the patient
with atopic dermatitis is not different from the
normal in his response to a primary antigen.
The patient with atopic dermatitis also re-
sponds in the same manner as do other patients
with chronic eczema and patients with certain
other skin diseases to a primarily administered
antigen.
Schick
ControlPPDS1 PPDS2
+
+
+
+
+
No Response
+
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
Blasto Coc- Ilistocidio
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+
+
+
+
+
+
Mumps
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Schick
+
+
+
+
+
+
+
+
+
+
+
+
Lyg- I Lyg. Oidio- Trich- Dickranum Control mycin Phyton
+
+
+
+
+
+ +
+
+
+
+
+
+
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Antibody Sequence
It has been shown (10, 11, 12) that following
the injection of an antigen the first immuno-
globulin appears in the gamma M fraction of
the serum. Immunoglobulin sequence is the
same in patients with atopic dermatitis as it is
in other forms of eczema and in normal pa-
tients. The ability to form antibodies in the
immunoglobulin A fraction of the serum was
not determined. Future studies of antibody
titers in this immunoglobulin fraction may be
revealing. The route of administration of an
antigen is very important in determining im-
munoglobulin sequence. It will be interesting to
note the antibody response and immunoglobulin
sequence following the injection of this antigen
submucosally.
Delayed Immune Response
a) Skin tests. Thirty-one of thirty-two pa-
tients with atopic dermatitis presented one or
several positive skin tests. The patient that
gave negative responses to all skin tests was dis-
covered to have developed sarcoidosis with
mediastinal lymph nodes and cutaneous lesions.
b) DNCB. Patients with atopic dermatitis
were less easily sensitized to DNCB (Table V)
than were the other groups studied. DNCB will
sensitize over 90% of the normal population as
shown in other studies (7). Two factors may be
significant or responsible for the low rate of
sensitization in the group with atopic dermati-
tis. First, all the patients except two are Ne-
groes. In a previous study by Epstein et at.
(14) it was shown that Negroes are less easily
sensitized to DNCB. Another factor coild be
the lichenification of the skin of the atopic pa-
TABLE V
Delayed hypersensitivity— (DNCB sensitization)
Disease
Number
of
Patients
Primaryirritant
Re-
sponse
to2%
.Positive
Response to
c a enge
°
Atopic Dermatitis
Asthma and/or Hay
Fever—no dermatitis
Chronic Hand Eczema
Nummular Eczema
Psoriasis
Acne Vulgaris
39
6
13
10
15
2
39
6
13
10
15
2
30—76.9%
6—100%
12—92.3%
9—90%
13—86.6%
2—100%
Disease
Number Number
of of
patients grafts
Primary
rejection
Atopic dermatitis
Nummular eczema
Sarcoid
4
2
3
8
4
6
14—19 days
14—19 days
14—19 days
TABLE VII
Autografts
(14 Patients with Atopic Dermatitis)
Type of Autograft Total ofGrafts
Number
of Takes
Percentage
of Takes
90Normal skin to normal 20 18
skin
Normal skin to dis- 28 15 53
eased skin
Diseased skin to nor- 27 8 29
mal skin
Diseased skin to dis- 19 6 31
eased skin
tient, in which case the DNCB might not pene-
trate the stratum corneum, although only two
of our patients had obvious lichenification in
test sites. In our psoriatic group most of the
patients are Caucasian (12 of 15 patients). The
two patients who did not react to DNCB are
older (over 60 years), and this could very well
account for their lack of reactivity to DNCB.
c) Homo grafts. All patients rejected the set
of homografts in 14—19 days, appearing to be
immunologically competent regarding this form
of delayed hypersensitivity.
Auto grafts
Iii the present study, diseased skin was not as
easily transplanted to a normal site as was nor-
mal skin to a diseased site. Since the diseased
skin is acanthotic and has dermal infiltration
and edema, we can speculate that the metabolic
needs of the diseased skin exceed those of the
normal skin. Animal experimentation suggests
(16) that hyperplastic skin is more susceptible
than normal tissue to the effect of the temporary
anoxia to which a transplant is exposed follow-
ing grafting. Certainly in previous studies (17—
18) in which the skin either was hyperplastic
or had infiltrates in the dermis, the autografts
TABLE VI
Delayed hypersensitivity homo graft rejection
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did not take. In our patients the fact that dis-
eased skin could be transplanted more easily to
a normal site when the diseased skin was less
severely involved suggests at least that extent
of damage is inversely correlated with ability to
survive hostile alterations in the environment,
including anoxia.
5UMMART AND CONCLUsIONS
Patients with atopie dermatitis produce nor-
mal circulating antibody titers to the primary
VI antigen and to the Brueellin antigen.
Immune globulin sequence is normal in pa-
tients with atopie dermatitis.
Patients with atopie dermatitis are not as
easily sensitized to DNCB as are patients with
other forms of eczema.
Homograft rejection and skin responses to the
intradermal injection of bacterial and myeelial
antigens are normal in patients with atopie der-
matitis.
The normal atopie skin can be autografted to
a diseased site. The diseased atopie skin cannot
be easily autografted to a normal skin site.
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